MGD013

BIOLOGICAL2 trials

Sponsors

MacroGenics, Zai Lab (Shanghai) Co., Ltd.

Conditions

Head and Neck CancerSquamous Cell Carcinoma of Head and NeckUnresectable, Recurrent or Metastatic MelanomaUntreated Mucosal or Acral Lentiginous Melanoma

Phase 1

A Study to Evaluate the Safety and Efficacy of MGD013 in Patients With Melanoma

TerminatedNCT04653038

Zai Lab (Shanghai) Co., Ltd.Unresectable, Recurrent or Metastatic Melanoma, Untreated Mucosal or Acral Lentiginous Melanoma

Start: 2020-10-29End: 2022-03-02Updated: 2024-01-29

Phase 2

Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck

WithdrawnNCT04129320

MacroGenicsHead and Neck Cancer, Squamous Cell Carcinoma of Head and Neck

Start: 2019-10-31End: 2022-10-31Updated: 2022-02-08

Related Papers

Abstract CT208: Tebotelimab, a PD-1/LAG-3 bispecific antibody, in patients with untreated, unresectable, recurrent or metastatic, mucosal melanoma: An open-label, single-arm, Phase 1 study

Cancer Research2023-04-143 citations

Antibodies to watch in 2020.

2020-01-01328 citations